Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF – Get Free Report) was the recipient of a large decline in short interest in October. As of October 30th, there was short interest totaling 29,458 shares, a decline of 47.6% from the October 15th total of 56,196 shares. Based on an average daily trading volume, of 7,414 shares, the short-interest ratio is currently 4.0 days.
Medexus Pharmaceuticals Trading Up 5.1%
Shares of OTCMKTS MEDXF traded up $0.19 during trading on Monday, reaching $4.01. The company had a trading volume of 37,695 shares, compared to its average volume of 13,009. Medexus Pharmaceuticals has a 12-month low of $1.80 and a 12-month high of $4.01. The business’s 50-day moving average is $3.55 and its 200 day moving average is $3.07.
Medexus Pharmaceuticals Company Profile
Medexus Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing medicines for patients with underserved medical needs. Its activities span areas including hematology, oncology, rheumatology and allergy. In the United States, its marketed products include IXINITY, a recombinant factor IX treatment for hemophilia B; Gleolan, used to help surgeons visualize certain brain tumors; and Rasuvo, a methotrexate injection for inflammatory conditions. In Canada, Medexus markets products including Rupall, an antihistamine, and Metoject, a methotrexate product.
Featured Stories
- Five stocks we like better than Medexus Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
